230 related articles for article (PubMed ID: 26186440)
1. Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.
Sued O; Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Claramonte X; Plana M; Tuset M; Pumarola T; Gallart T; Gatell JM; Miró JM
PLoS One; 2015; 10(7):e0131651. PubMed ID: 26186440
[TBL] [Abstract][Full Text] [Related]
2. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.
Goujard C; Emilie D; Roussillon C; Godot V; Rouzioux C; Venet A; Colin C; Pialoux G; Girard PM; Boilet V; Chaix ML; Galanaud P; Chene G;
AIDS; 2012 Sep; 26(15):1895-905. PubMed ID: 22842994
[TBL] [Abstract][Full Text] [Related]
3. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
[TBL] [Abstract][Full Text] [Related]
5. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
6. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
[TBL] [Abstract][Full Text] [Related]
7. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.
Goujard C; Marcellin F; Hendel-Chavez H; Burgard M; Meiffrédy V; Venet A; Rouzioux C; Taoufik Y; El Habib R; Beumont-Mauviel M; Aboulker JP; Lévy Y; Delfraissy JF;
AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1105-13. PubMed ID: 17919105
[TBL] [Abstract][Full Text] [Related]
8. Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV.
Lévy Y; Thiébaut R; Gougeon ML; Molina JM; Weiss L; Girard PM; Venet A; Morlat P; Poirier B; Lascaux AS; Boucherie C; Sereni D; Rouzioux C; Viard JP; Lane C; Delfraissy JF; Sereti I; Chêne G;
AIDS; 2012 Mar; 26(6):711-20. PubMed ID: 22301410
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
10. [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].
Rey D; Schmitt MP; Hess-Kempf G; Krantz V; Partisani M; Bernard-Henry C; Lang JM
Pathol Biol (Paris); 2001 Sep; 49(7):559-66. PubMed ID: 11642019
[TBL] [Abstract][Full Text] [Related]
11. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.
Plana M; Garcia F; Oxenius A; Ortiz GM; Lopez A; Cruceta A; Mestre G; Fumero E; Fagard C; Sambeat MA; Segura F; Miró JM; Arnedo M; Lopalcos L; Pumarola T; Hirschel B; Phillips RE; Nixon DF; Gallart T; Gatell JM
J Acquir Immune Defic Syndr; 2004 Jul; 36(3):791-9. PubMed ID: 15213562
[TBL] [Abstract][Full Text] [Related]
12. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.
Henry K; Katzenstein D; Cherng DW; Valdez H; Powderly W; Vargas MB; Jahed NC; Jacobson JM; Myers LS; Schmitz JL; Winters M; Tebas P;
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):140-8. PubMed ID: 16760795
[TBL] [Abstract][Full Text] [Related]
13. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
14. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.
Pai NP; Tulsky JP; Lawrence J; Colford JM; Reingold AL
Cochrane Database Syst Rev; 2005 Oct; (4):CD005482. PubMed ID: 16235406
[TBL] [Abstract][Full Text] [Related]
15. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
[TBL] [Abstract][Full Text] [Related]
16. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
[TBL] [Abstract][Full Text] [Related]
17. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.
García F; Plana M; Ortiz GM; Bonhoeffer S; Soriano A; Vidal C; Cruceta A; Arnedo M; Gil C; Pantaleo G; Pumarola T; Gallart T; Nixon DF; Miró JM; Gatell JM
AIDS; 2001 Jun; 15(9):F29-40. PubMed ID: 11416735
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.
Yazdanpanah Y; Wolf LL; Anglaret X; Gabillard D; Walensky RP; Moh R; Danel C; Sloan CE; Losina E; Freedberg KA;
Antivir Ther; 2010; 15(3):351-61. PubMed ID: 20516555
[TBL] [Abstract][Full Text] [Related]
19. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.
Moltó J; Ruiz L; Romeu J; Martínez-Picado J; Negredo E; Tural C; Sirera G; Clotet B
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1283-8. PubMed ID: 15650419
[TBL] [Abstract][Full Text] [Related]
20. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
